Optimal frontline management of mantle cell lymphoma: can we agree?

Tang, Catherine; Kuruvilla, John

doi:10.1080/17474086.2018.1537778

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commonly used chemoimmunotherapy regimens include rituximab-based regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or alternating R-CHOP/R-DHAP (rituximab, dexamethasone, high-dose cytarabine, and cisplatin). Occasionally, hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with methotrexate and cytarabine) is adopted [ 3 , 9 , 10 , 11 ]. As patients aged >65–70 years are typically ineligible for transplant, management focuses on less toxic treatment strategies such as bendamustine and rituximab (BR) and R-CHOP [ 6 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada

Anglin

Elia-Pacitti²,

Eberg³

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Background: With the emergence of therapies for mantle cell lymphoma (MCL), understanding the treatment patterns and burden of illness among older patients with MCL in Canada is essential to inform decision making. Methods: A retrospective study using administrative data matched individuals aged ≥65 who were newly diagnosed with MCL between 1 January 2013 and 31 December 2016 with general population controls. Cases were followed for up to 3 years in order to assess healthcare resource utilization (HCRU), healthcare costs, time to next treatment or death (TTNTD), and overall survival (OS); all were stratified according to first-line treatment. Results: This study matched 159 MCL patients to 636 controls. Direct healthcare costs were highest among MCL patients in the first year following diagnosis (Y1: CAD 77,555 ± 40,789), decreased subsequently (Y2: CAD 40,093 ± 28,720; Y3: CAD 36,059 ± 36,303), and were consistently higher than the costs for controls. The 3-year OS after MCL diagnosis was 68.6%, with patients receiving bendamustine + rituximab (BR) experiencing a significantly higher OS compared to patients treated with other regimens (72.4% vs. 55.6%, p = 0.041). Approximately 40.9% of MCL patients initiated a second-line therapy or died within 3 years. Conclusion: Newly diagnosed MCL presents a substantial burden to the healthcare system, with almost half of all patients progressing to a second-line therapy or death within 3 years.

show abstract

Section: Introductionmentioning

confidence: 99%